Blueprint Medicines Q2 2024 GAAP EPS $(0.80) Beats $(1.30) Estimate, Sales $138.157M Beat $103.575M Estimate
Portfolio Pulse from Benzinga Newsdesk
Blueprint Medicines (NASDAQ:BPMC) reported Q2 2024 GAAP EPS of $(0.80), beating the estimate of $(1.30). Sales were $138.157M, surpassing the $103.575M estimate and showing a 139.98% increase from the same period last year.
August 01, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Blueprint Medicines reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.80) beating the $(1.30) estimate and sales of $138.157M surpassing the $103.575M estimate. Sales increased by 139.98% YoY.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year sales increase, is likely to positively impact BPMC's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100